Erectile Dysfunction Drugs Market Size Worth USD 5.1 billion by 2032 at 6.5% CAGR, Says AMR

Allied Market Research published a report, titled, "Erectile Dysfunction Drugs Market By Product (Sildenafil, Avanfil, Tadalafil, Udenafil, and Others.), By Mode of Administration (Oral Medications and Injectable Medication), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy): Global Opportunity Analysis and Industry Forecast, 2022-2032." According to the report, the global erectile dysfunction drugs industry was estimated at USD 2.6 billion in 2022 and is anticipated to hit USD 5.1 billion by 2032, registering a CAGR of 6.5% from 2023 to 2032.

Top Erectile Dysfunction Drugs Companies:-

• Pfizer Inc.
• Eli Lilly and Company
• Teva Pharmaceutical Industries Ltd.
• Sanofi
• Bayer AG
• Vivus LLC.
• Adamed
• Glenmark Pharmaceuticals Limited
• Cipla Ltd
• Sun Pharmaceutical Industries Limited

Get Sample PDF Report with Graphs and Figures Here: https://www.alliedmarketresearch.com/request-sample/382

What are the factors driving the Erectile Dysfunction Drugs Market?

The global erectile dysfunction drugs market is driven by factors such as an Increase in the prevalence of erectile dysfunction due to diabetes, obesity, and sedentary lifestyle, easy accessibility of erectile dysfunction drugs, and surge in awareness about erectile dysfunction. However, side effects associated with erectile dysfunction drugs such as nasal congestion, blurred vision, and flushing are hampering the erectile dysfunction drugs market growth. On the contrary, an increase in R&D activities in erectile dysfunction treatment, high growth potential in developing countries, and a rise in new erectile dysfunction drugs launch are expected to offer remunerative opportunities for expansion of the erectile dysfunction drugs market during the forecast period.

Global Erectile Dysfunction Drugs Market Segmentation:-

Based on product, the sildenafil segment held the highest market share in 2022, accounting for more than half of the global erectile dysfunction drugs market revenue and is estimated to maintain its leadership status throughout the forecast period. The same segment is projected to manifest the highest CAGR of 7.1% from 2023 to 2032. This is because it is easily accessible, highly potent to treat erectile dysfunction, and it is available in various concentrations such as Sildenafil 20mg, sildenafil 50mg, and sildenafil 100mg.

Based on mode of administration, the oral medication segment held the highest market share in 2022, accounting for more than four-fifths of the global erectile dysfunction drugs market revenue and is estimated to dominate the market in terms of revenue during the forecast period. The same segment is estimated to manifest the highest CAGR of 6.8% from 2023 to 2032, owing to increase in demand for oral medications as it is easy to administer, highly effective, and widely available in the market as compared with injectable medication.

Based on the distribution channel, the hospital pharmacy segment accounted for the largest share in 2022, contributing to more than two-fifths of the global erectile dysfunction drugs market revenue and is expected to rule the roost in terms of revenue throughout the forecast timeframe. This segment is projected to maintain the highest CAGR of 7.2% during the forecast period, owing to an increase in the sale of prescription medication from hospitals and the availability of erectile dysfunction drugs in various concentrations through hospital pharmacies.

Based on region, North America held the highest market share in terms of revenue in 2022, accounting for around two-fifths of the global erectile dysfunction drugs market revenue and is estimated to lead the trail throughout the forecast period. The growth is attributed to an increase in accessibility of erectile dysfunction drugs and rise in product approvals. However, the Asia-Pacific region is expected to witness the fastest CAGR of 7.5% from 2023 to 2032, owing to rise in awareness of erectile dysfunction, surge in healthcare expenditure, and an increase in the prevalence of various chronic diseases such as diabetes and obesity.

Purchase the Report: https://www.alliedmarketresearch.com/purchase-enquiry/382

Our Market Research Solution Provides You Answer to Below Mentioned Question:

• Which are the driving factors responsible for the growth of market?
• Which are the roadblock factors of this market?
• What are the new opportunities, by which market will grow in coming years?
• What are the trends of this market?
• Which are main factors responsible for new product launch?
• How big is the global & regional market in terms of revenue, sales and production?
• How far will the market grow in forecast period in terms of revenue, sales and production?
• Which region is dominating the global market and what are the market shares of each region in the overall market in 2022?
• How will each segment grow over the forecast period and how much revenue will these segments account for in 2030?
• Which region has more opportunities?

By Region Outlook

• North America
(U.S., Canada, Mexico)
• Europe
(Germany, France, UK, Italy, Spain, Rest of Europe)
• Asia-Pacific
(Japan, China, India, Rest of Asia-Pacific)
• LAMEA
(Brazil, Saudi Arabia, South Africa, Rest of LAMEA)

Contact Details:

David Correa
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
help@alliedmarketresearch.com

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

This release was published on openPR.